le Hua, MD
Neurology · Las Vegas, NVNPI 1215197892
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.1%. Reporting peaked in 2019 at $104,083 and has fallen 75.7% since, to $25,305 in 2025. Among neurology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 393 payments — averaging $980.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$81K
- Sanofi$64K
- Genentech USA, Inc.$46K
- Novartis$37K
- Novartis Pharma AG$31K
- Bristol Myers Squibb$26K
- plus $100K from 14 others
Across 280 payments — averaging $18,566 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.1M
- Genentech, Inc.$1.2M
- AbbVie$613K
- Biogen$539K
- TG Therapeutics, Inc.$202K
- Adamas Pharmaceuticals, Inc.$173K
- plus $414K from 5 others
What the payments were for
- Consulting fees$217,17456%
- Speaking & faculty fees$115,75530%
- Travel & lodging$39,89510%
- Food & beverage$11,4683%
- Education$2180%
- Gifts$9110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 85 | $81,321 |
| Sanofi | 48 | $64,128 |
| Genentech USA, Inc. | 44 | $45,649 |
| Novartis | 51 | $37,319 |
| Novartis Pharma AG | 13 | $30,577 |
| Bristol Myers Squibb | 27 | $26,004 |
| Biogen | 44 | $24,851 |
| TG Therapeutics, Inc. | 16 | $14,952 |
| Amgen(2 entities) | 28 | $13,991 |
| Merck Kgaa | 5 | $9,855 |
| Merck Healthcare Kgaa | 4 | $9,850 |
| AstraZeneca(2 entities) | 11 | $9,030 |
| E.r. Squibb & Sons, L.L.C. | 5 | $8,890 |
| Genentech, Inc. | 4 | $4,970 |
| Greenwich Biosciences, Inc. | 1 | $3,808 |
| Teva Pharmaceuticals USA, Inc. | 1 | $70 |
| AbbVie | 2 | $57 |
| UCB, Inc. | 1 | $41 |
| Mallinckrodt Hospital Products Inc. | 2 | $40 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUBAGIO$34,339
- Mavenclad$32,926
- OCREVUS$32,234
- BAF312A_MAYZENT_NEUROSCIENCE$15,341
- TYSABRI$14,562
- UPLIZNA$13,406
- ZEPOSIA$12,742
- BRIUMVI$11,466
- ARZERRA$9,350
- Ozanimod$9,259
- LEMTRADA$7,899
- KESIMPTA$7,176
- Rebif$5,790
- Evobrutinib$4,170
- MAYZENT$3,317
- DISEASE STATE$3,078
- ULTOMIRIS$2,840
- Rhapsido$2,700
- ADAKVEO$2,394
- Vumerity$2,004
How this compares
$385,421 in reported general payments places this provider in the 95th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnspryngSatralizumab-Mwge | 15 | $254,446 |
| Kesimpta PenOfatumumab | 28 | $234,381 |
| TysabriNatalizumab | 18 | $160,759 |
| AubagioTeriflunomide | 16 | $149,837 |
| MayzentSiponimod | 11 | $107,582 |
| CopaxoneGlatiramer Acetate | 11 | $60,359 |
| Glatiramer Acetate | 18 | $35,752 |
| Dalfampridine ErDalfampridine | 99 | $26,161 |
| Teriflunomide | 17 | $4,065 |
| Carbamazepine ErCarbamazepine | 11 | $3,533 |
| Gabapentin | 102 | $2,407 |
| Baclofen | 60 | $1,082 |
| Modafinil | 23 | $1,041 |
| Duloxetine Hcl | 36 | $720 |
| Pregabalin | 32 | $673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Enspryng | $45,649 | $254,44615 claims |
| BiogenTysabri | $24,851 | $160,75918 claims |
| SanofiAubagio | $64,128 | $149,83716 claims |
| NovartisMayzent | $37,319 | $107,58211 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $70 | $60,35911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 145 neurology providers in Nevada.
Other neurology in Las Vegas
- Zoltan MariLas Vegas$629K
- Fan ZhangLas Vegas$398K
- Mehdi AnsariniaLas Vegas$306K
- Carrie HershLas Vegas$209K
- Shanker DixitLas Vegas$137K
- Charles KamenLas Vegas$124K
- Toya MaloneLas Vegas$123K
- Nicole TheuvenetLas Vegas$120K
- Kevin XieLas Vegas$46K
- Charles BernickLas Vegas$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.